Phase III, Randomized, Placebo-Controlled Study of Once-Daily Oral Zibotentan (ZD4054) in Patients With Non-Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer and Prostatic Diseases - United Kingdom
doi 10.1038/pcan.2013.2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Olaparib Combined With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial

The Lancet Oncology
Oncology
2018English

Corrections To: Once-Daily Controlled-Release Pregabalin in the Treatment of Patients With Fibromyalgia: A Phase III, Double-Blind, Randomized Withdrawal, Placebo-Controlled Study

Current Medical Research and Opinion
Medicine
2017English

Phase II Randomized Study of Figitumumab Plus Docetaxel and Docetaxel Alone With Crossover for Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research
Cancer ResearchOncology
2014English

Phase 1 Trial of High-Dose Exogenous Testosterone in Patients With Castration-Resistant Metastatic Prostate Cancer

European Urology
Urology
2009English

Exploratory Analysis of the Visceral Disease Subgroup in a Phase III Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer and Prostatic Diseases
Cancer ResearchOncologyUrology
2013English

PCN120 Quality of Life Among German Patients With Metastatic Castration-Resistant Prostate Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Lipegfilgrastim in Patients With Non-Small Cell Lung Cancer Receiving Myelosuppressive Therapy

SpringerPlus
Multidisciplinary
2015English

Phase I Trial With a Combination of Docetaxel and 153Sm-Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2011English

Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial

The Lancet Oncology
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy